Barclays Lowers Ryan Specialty Price Target to $41
Barclays lowered the firm's price target on Ryan Specialty to $41 from $45 and keeps an Overweight rating on the shares. The firm adjusted targets in the insurance group as part of a Q1 preview. Premium growth and broker organic growth "are likely to remain sluggish," the analyst tells investors in a research note. However, Barclays sees solid margins and strong capital deployment still contributing to reported book value growth in Q1.
Trade with 70% Backtested Accuracy
Analyst Views on RYAN
About RYAN
About the author

Company Overview: Ryan Specialty Holdings is a company involved in the insurance sector, focusing on specialty insurance and reinsurance services.
Stock Price Adjustment: The stock price of Ryan Specialty Holdings has been cut from $56 to $42, indicating a significant decrease in market valuation.
Company Overview: Ryan Specialty Holdings is a company involved in the insurance and reinsurance sector.
Stock Price Adjustment: Barclays has reduced its target price for Ryan Specialty Holdings' stock from $45 to $41.
- Earnings Release Schedule: Ryan Specialty Holdings, Inc. will announce its Q1 2026 financial results after market close on April 30, 2026, reflecting its ongoing growth in the specialty insurance sector.
- Conference Call Timing: The company will host a conference call at 4:45 PM Eastern Time on April 30, 2026, to discuss the financial results, which is expected to attract significant attention from investors and analysts.
- Webcast Access: Interested parties can register for the live webcast of the conference call through the company's Investor Relations website, ensuring to join at least 10 minutes prior to the scheduled start time for the latest updates.
- Replay Availability: A replay of the webcast will be available at ir.ryanspecialty.com for one year following the call, allowing investors who could not attend live to review the meeting content.
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions of these firms.
- Market Reaction Insight: While specific rating changes are not detailed, analysts' opinions typically influence investor decisions, potentially leading to stock price fluctuations.
- Investor Focus: For those considering buying FSLR stock, analysts' insights will serve as a crucial reference point, likely impacting their investment strategies.
- Rating Change Transparency: Comprehensive information on analyst rating changes can be found on Benzinga's analyst ratings page, providing deeper market insights to assist investors in making informed decisions.
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting the latest market perspectives on these stocks, which could influence investor decisions and market trends.
- Overview of Rating Changes: While specific upgrades and downgrades are not detailed, the overall rating changes may lead to short-term volatility in related stocks, prompting investors to stay alert.
- Expected Market Reaction: Analyst rating adjustments typically attract market attention, potentially affecting investor confidence and trading volumes, thereby impacting stock prices.
- Impact on Investor Decisions: Investors considering buying CAVA stock should pay attention to analysts' views to make more informed investment decisions, even though specific recommendations are not provided in this article.
Target Price Adjustment: Ryan Specialty Holdings has reduced its target price from $71 to $65.
Market Impact: This adjustment reflects changes in market conditions or company performance expectations.










